Georgia is currently home to 1949 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
NCT04903080
Recruiting
This is a Phase I study to evaluate the safety profile of a type of immune therapy called HER2 CAR T cells (short for HER2 chimeric antigen receptor T cells). In addition to looking for side effects, we will study how well this treatment works against a brain tumor called ependymoma that has come back after treatment (recurrent) or has not responded well to treatment (progressive) in children. The HER2 CAR T cells used in this trial are made from the patient's own blood. A new gene, called the H... Read More
Gender:
ALL
Ages:
Between 1 year and 22 years
Trial Updated:
08/05/2025
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Ependymoma
Register for Updates
A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04782258
Recruiting
To evaluate the safety of tolvaptan in pediatric subjects with ARPKD
Gender:
ALL
Ages:
Between 28 days and 18 years
Trial Updated:
08/05/2025
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Autosomal Recessive Polycystic Kidney (ARPKD)
Register for Updates
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
NCT04557956
Recruiting
This phase I/II trial investigates the best dose, possible benefits and/or side effects of tazemetostat in combination with dabrafenib and trametinib in treating patients with melanoma that has a specific mutation in the BRAF gene (BRAFV600) and that has spread from where it first started (primary site) to other places in the body (metastatic). Tazemetostat, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tazemetostat i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Register for Updates
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
NCT07113522
Recruiting
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/04/2025
Locations: Mirador Therapeutics Selected Site, Snellville, Georgia
Conditions: Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
Register for Updates
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
NCT07104240
Recruiting
This clinical trial compares the effect of a vaccine promotional intervention, TweenVax, to standard of care vaccination promotion practices on rates of human papillomavirus (HPV) vaccination in adolescents. HPV vaccination has been identified as a priority for cancer prevention and control by the Cancer Moonshot Blue Ribbon Panel, which estimated that increasing HPV vaccination rates can prevent 400,000 HPV-related cancers in the next 5-10 years. The goal is for HPV vaccinations to be completed... Read More
Gender:
ALL
Ages:
9 years and above
Trial Updated:
08/04/2025
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Human Papillomavirus-Related Carcinoma
Register for Updates
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
NCT07038876
Recruiting
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syn... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
08/04/2025
Locations: Clinical Site, Atlanta, Georgia
Conditions: Schizophrenia
Register for Updates
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785
Recruiting
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Research Site, Atlanta, Georgia
Conditions: Hepatocellular Carcinoma
Register for Updates
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
NCT06851858
Recruiting
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/04/2025
Locations: Research Site, Canton, Georgia
Conditions: Endocrinology, Diabetes, Type II, Obesity
Register for Updates
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
NCT06828861
Recruiting
The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101. The main questions it aims to answer are: * Does ARD-101 improve the total score of the HQCT-9 (hyperphagia questionnaire for clinical trials, 9 questions)? * What medical problems do participants have when taking ARD-101? Researchers will compare ARD-101 to a placebo (a look-alike substance that con... Read More
Gender:
ALL
Ages:
13 years and above
Trial Updated:
08/04/2025
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Hyperphagia, Prader-Willi Syndrome
Register for Updates
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319
Recruiting
This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments. Study details include: * The study duration will be approximately 64 weeks for participants not transiti... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/04/2025
Locations: Private Practice - Dr. David Kavtaradze- Site Number : 8400081, Cordele, Georgia
Conditions: Asthma
Register for Updates
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824
Recruiting
This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the metastatic sett... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: University Cancer & Blood Center, LLC, Athens, Georgia
Conditions: PD-L1-positive Metastatic NSCLC
Register for Updates
Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease
NCT06621602
Recruiting
This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
08/04/2025
Locations: Atlanta NeuroScience Institute ANI, Atlanta, Georgia
Conditions: REM Behavior Disorder, Parkinson Disease
Register for Updates